**Zenith Healthcare Limited** is an Ahmedabad-based pharmaceutical company specializing in the manufacturing, marketing, and trading of diverse pharmaceutical formulations. The company operates through a single primary segment—**Pharmaceuticals**—with a product portfolio spanning **tablets, capsules, oral liquids, and injectables**. With a legacy of over **30 years** under its current leadership, the company is transitioning toward an asset-light, export-oriented growth model. --- ### Strategic Growth Model: Asset-Light Expansion Zenith Healthcare is pursuing a deliberate strategy to scale production capacity while minimizing capital expenditure (**CAPEX**). By opting for lease-based infrastructure rather than land acquisition, the company aims to preserve liquidity and reduce **long-term interest costs**. * **The Achyut Healthcare Partnership:** A cornerstone of this strategy is a significant **Related Party Transaction** with **M/s. Achyut Healthcare Limited**. Zenith has secured a lease for a manufacturing facility in **Bhat, Ahmedabad**, including factory buildings, plant, and machinery. * **Lease Terms & Timeline:** The agreement spans **9 years**, effective **January 1, 2025**. Lease payments are scheduled to commence on **April 1, 2025**, or the date of commercial production, whichever is later. * **Operational Control:** Despite the third-party ownership of the facility, Zenith maintains strict quality control by deploying its own **trained and qualified manpower** to manage operations. * **Capacity Drivers:** This expansion is fueled by a growing order book and strong market acceptance in both **domestic supply** and **international export** channels. --- ### Manufacturing Infrastructure & Production Capacity The company’s manufacturing footprint is concentrated in the industrial hubs of Gujarat, optimized for logistical efficiency and cost control. | Asset Type | Location / Details | | :--- | :--- | | **Primary Works** | 388/34, Changodar Industrial Estate, Sarkhej-Bavla Highway, Ahmedabad | | **Storage/Godown** | 56/B, Changodar Industrial Estate, Vibhag-1, Ahmedabad | | **Strategic Facility** | **M/s. Achyut Healthcare Limited** (Village: Bhat, Ahmedabad) | | **Lease Duration** | Standard office/store leases range from **11 months to 5 years**; Strategic facility lease is **9 years**. | **Monthly Production Capacity (Per Shift):** * **Tablets:** **5 Crore** units * **Capsules:** **1 Crore** units * **Oral Liquids:** **0.1 Crore** bottles --- ### Financial Performance & Capital Allocation The most recent fiscal period showed a contraction in scale, reflecting broader market challenges and a shift in operational focus. **Key Financial Metrics (FY 2024-25 vs. FY 2023-24):** | Metric | FY 2024-25 | FY 2023-24 | Change (%) | | :--- | :--- | :--- | :--- | | **Revenue from Operations** | **₹11.76 Crore** | **₹14.73 Crore** | **-20.16%** | | **Net Profit** | **₹6.84 Lakhs** | **₹20.35 Lakhs** | **-66.39%** | | **Export Income** | **₹8.21 Crore** | - | - | | **Export Expenditure** | **₹16.93 Lakhs** | - | - | **Capital Management & Dividends:** * **Dividend Policy:** The company has **not recommended a dividend** for the current year, opting instead to reinvest earnings. * **Reserves:** In compliance with **Section 134 (3) (j)** of the Companies Act, 2013, the total net profit of **₹6.84 Lakhs** was transferred to the **General Reserve**. * **Audit Exemptions:** Due to an overall turnover of **less than ₹100 Crores** and individual product turnover **under ₹25 Crores**, the company is exempt from mandatory Cost Audits. --- ### Global Market Penetration & Regulatory Compliance Zenith is actively diversifying its geographic footprint to mitigate domestic pricing pressures and tap into emerging pharmaceutical markets. * **International Footprint:** The company has successfully obtained **Plant Registration** in **Kenya, Nigeria, and Uzbekistan**. While several product registrations are currently **pending**, these regions are identified as primary drivers for future revenue. * **Domestic Regulatory Environment:** The company operates under the **Drug Price Control Order (DPCO)**. While it complies with all pricing mandates, the management notes that DPCO price controls on over **650 products** limit domestic pricing power. * **Compliance Standards:** Zenith does not manufacture prohibited drugs, cosmetics, or psychotropic substances. The operating cycle for asset/liability classification is fixed at **12 months**. --- ### Risk Management & Mitigation Framework The Board and Audit Committee oversee a formal risk management process to address volatility in the pharmaceutical sector. | Risk Category | Impact Area | Mitigation Strategy | | :--- | :--- | :--- | | **Regulatory/Pricing** | **DPCO** price caps | Diversifying product mix; aggressive expansion into **CIS and African markets**. | | **Financial/Currency** | Exchange rate & interest volatility | Utilization of **forward booking** and proactive vendor development. | | **Credit Risk** | Counterparty default | Partnering with top-tier banks (**PNB, SBI, HDFC**); maintaining minimal cash reserves (one month's cost). | | **Operational Cost** | Lease fees vs. CAPEX | Balancing higher per-unit production costs against reduced long-term debt/interest. | | **Human Capital** | Talent retention | Strategic **Learning & Development (L&D)** and talent management initiatives. | --- ### Governance, Leadership & Service Providers The company maintains a stable leadership structure and adheres to rigorous auditing standards to ensure transparency. * **Executive Leadership:** **Mr. Mahendra C. Raycha** serves as Chairman and Managing Director. He was re-appointed for a **3-year term** starting July 1, 2023. His remuneration is capped at **₹2,00,000 per month**. * **Audit Oversight:** * **Statutory Auditors:** **M/s. Doshi Doshi & Co.** (Appointed through **2029**). * **Internal Auditors:** **M/s. Mohta Khetawat & Co.** * **Secretarial Auditors:** **M/s. Kamlesh M Shah & Co.** (Appointed for **FY 2025-26 to 2029-30**). * **Internal Controls:** No instances of fraud were reported under **Section 143(12)**. The company maintains **adequate insurance** for all physical assets, employees, and third-party liabilities. * **Shareholder Services:** **Bigshare Services Pvt. Ltd.** acts as the Registrar and Share Transfer Agent.